This is the authors' abstract. We don't add key points for this paper.
Long non-coding RNA (lncRNA) molecules, which are over 200 nucleotides long without protein-coding potential, play crucial roles in various biological processes and the progression of tumors. Emerging evidence shows that lncRNA forkhead box D3 antisense 1 (FOXD3-AS1) is transcribed from a gene on chromosome 1p31.3, comprising six exons, and is expected to enhance the expression of specific genes. FOXD3-AS1 functions mainly by promoting cancer progression through interactions with target proteins, binding to 11 microRNAs (miRNAs), and influencing key signaling pathways such as TGF-β/Smad and PI3K/AKT. These molecular mechanisms collectively drive malignant characteristics like cell proliferation, invasion, migration, apoptosis, and epithelial-mesenchymal transition (EMT) in cancer cells. Clinical research has shown that elevated FOXD3-AS1 levels are linked to tumor volume enlargement, progression in clinical staging, increased risk of metastasis, and poor prognosis. This review provides an in-depth analysis of the functional role, molecular mechanisms, and clinical significance of FOXD3-AS1 in malignant tumors, with a focus on its potential as a diagnostic biomarker and therapeutic target in cancer treatment.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: